Seven criteria, each scored 0 to 100 on a published scale, weighted into one number.
Weak. Sanara MedTech Inc. scores higher than 23% of the 2,291 companies Ryufin scores.
Carried by earnings quality, held back by return on capital and valuation.
Healthcare median 18 · all companies 54
The biggest move was up 6 points from 2023 to 2025, mostly valuation.
26% of the score, 30% here after data gaps
Sanara MedTech Inc. is valued at 32.5x its operating profit before acquisition amortisation (EBITA), including debt: a very rich multiple.
18% of the score, 20% here after data gaps
Over 7 years the business earned -13% a year after tax on the capital it uses.
16% of the score, 18% here after data gaps
No operating profit over the period, so nothing was earned to reinvest.
14% of the score, 16% here after data gaps
How management spends the money: shares bought back or issued, and whether assets grow faster than the business they serve.
Taken out: its 12% is shared by the others
Margins have been too thin to measure a cycle against.
8% of the score, 9% here after data gaps
What the debt weighs against the profit that has to carry it.
6% of the score, 7% here after data gaps
Whether the reported profit arrives as cash, and whether the accounts show the usual signs of stretching.
Each criterion earns 0 to 100 points on the scale drawn under it, and the RyuScore is their average weighted 26, 18, 16, 14, 12, 8 and 6. Scales bend in the company's favour between their ends, so an ordinary figure is never already near zero. For SMTI, cycle position could not be measured from the filings, so it is taken out and the remaining weights scale up.
Built from the company's annual and quarterly filings with the SEC and today's share price. Banks, insurers and property trusts are not scored: their debt is their raw material, so these yardsticks mean something else there. Figures as of 2026-06-30, latest annual report FY2025.
Ranks #13 of 21 by RyuScore